HCG · NSE
Healthcare Global Enterprises Limited
₹708.25
+3.07% (+₹21.1)
Prev. close
₹687.15
Volume
82,273
Delivery %
48.7%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Axis Securities forecasts an upside potential of 12.2% for Healthcare Global Enterprises, with a target price of Rs 820.…” | Axis Securities AnalysisAxis Securities | Healthcare Global Enterprises | PENDING |
Fundamentals
About Healthcare Global Enterprises Limited
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services, including patient care, psychological support, nutrition, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, yoga therapy, bone marrow transplant, organ-specific oncology, radiation oncology, liver transplantation, radiology and imaging, clinical laboratory, day care chemotherapy center, home health care, preventive and psycho oncology, translational and nuclear medicine, oncodermatology, paediatric and gynaecologic oncology, anaesthesiology, and orthopaedic oncology. In addition, the company offers gastrointestinal and thoracic oncology, breast surgical oncology, and pain and palliative services. Further, it operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care; and provides oncology diagnostics services, including biomarkers, translational research, and clinical research services under the Triesta Sciences brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Manish Mattoo
Headquarters
Bengaluru
Employees
6,761
Website
hcgoncology.comExchange
View on NSE ↗Key stats
Market cap
₹10,574.33 Cr
P/E ratio (TTM)
448.3
EPS (TTM)
₹1.58
Beta (1Y · daily vs NIFTY 50)
0.72
Beta (5Y · monthly vs NIFTY 50)
0.27
Shares float
5.95 Cr
EPS · quarter ended Jun 2026
₹0.92
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,013.44 Cr | ₹1,397.79 Cr | ₹1,694.44 Cr | ₹1,912.12 Cr | ₹2,222.85 Cr | ₹2,545.41 Cr | |
| EBITDA | ₹50.09 Cr | ₹345.26 Cr | ₹302.75 Cr | ₹350.43 Cr | — | — |
| ₹-193.46 Cr | ₹53.73 Cr | ₹29.34 Cr | ₹48.14 Cr | ₹44.41 Cr | ₹13.76 Cr | |
| Diluted EPS | ₹-17.02 | ₹3.97 | ₹2.1 | ₹3.43 | ₹3.14 | ₹0.96 |
EBITDA has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,031.00 Cr | ₹2,218.00 Cr | ₹2,311.00 Cr | ₹2,701.00 Cr | ₹3,540.00 Cr | ₹3,920.00 Cr | |
| — | ₹914.68 Cr | ₹901.20 Cr | ₹1,274.36 Cr | ₹1,837.22 Cr | ₹1,735.35 Cr | |
| Stockholders' equity | ₹697.00 Cr | ₹870.00 Cr | ₹860.00 Cr | ₹825.00 Cr | ₹922.00 Cr | ₹1,332.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹121.00 Cr | ₹220.00 Cr | ₹252.00 Cr | ₹285.00 Cr | ₹317.00 Cr | ₹347.00 Cr | |
| Investing cash flow | ₹-171.10 Cr | ₹124.58 Cr | ₹-133.02 Cr | ₹-225.73 Cr | ₹-487.75 Cr | ₹-177.47 Cr |
| ₹112.00 Cr | ₹-155.00 Cr | ₹-140.00 Cr | ₹-64.00 Cr | ₹-42.00 Cr | ₹241.00 Cr | |
| Capital expenditure | ₹-35.00 Cr | ₹-71.00 Cr | ₹-133.00 Cr | ₹-186.00 Cr | ₹-209.00 Cr | ₹-292.00 Cr |
| End cash position | ₹2.86 Cr | ₹192.69 Cr | ₹171.18 Cr | ₹166.01 Cr | ₹-47.05 Cr | ₹363.23 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26–Jun 26(3Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 68.41% | 71.02% | 71.44% | 71.43% | 71.42% | 71.39% | 71.38% | 71.37% | 71.35% | 71.30% | 71.29% | 71.28% | 71.25% | 71.23% | 71.22% | 62.46% | 63.78% | 63.77% | 64.21% |
| Public | 31.60% | 28.99% | 28.56% | 28.57% | 28.58% | 28.61% | 28.62% | 28.63% | 28.65% | 28.70% | 28.71% | 28.72% | 28.75% | 28.77% | 28.78% | 37.54% | 36.22% | 36.23% | 35.79% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Healthcare Global Enterprises Limited | ₹10,259.30 Cr | ₹708.25 | 443.3 | 7.70 | 1.0% | 1.30 | +14.6% | +7.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Show all 11
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
11 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.